Fenwick Represents Audentes Therapeutics in $231.4 Million Common Stock Offering

January 31, 2018

​​Fenwick & West represented Audentes Therapeutics, Inc. (NASDAQ: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with life-threatening rare diseases, in its $231.4 million offering of common stock. Audentes sold 6,612,500 shares of its common stock at a public offering price of $35.00 per share, which included the exercise in full by the underwriters of their option to purchase 862,500 additional shares of common stock.

BofA Merrill Lynch, Cowen and Leerink Partners acted as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager.

The Fenwick transaction team was led by corporate lawyers Robert Freedman, Effie Toshav, Julia Forbess, Jane Jiang, Shiva Hippely and Elena Moreno Cloutier; and technology transactions lawyers Dan Becker and Stefano Quintini.